Hikma Pharmaceuticals (LON:HIK) Given “Buy” Rating at Peel Hunt

Peel Hunt reaffirmed their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report issued on Friday, Marketbeat Ratings reports. Peel Hunt currently has a GBX 2,170 price target on the stock.

HIK has been the subject of a number of other reports. JPMorgan Chase & Co. lowered their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday. Berenberg Bank reduced their target price on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of GBX 2,416.

Hikma Pharmaceuticals Trading Up 3.9%

HIK stock traded up GBX 60 during midday trading on Friday, reaching GBX 1,582. 1,155,675 shares of the company traded hands, compared to its average volume of 1,297,659. The firm has a market capitalization of £3.50 billion, a price-to-earnings ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a 52-week low of GBX 1,522 and a 52-week high of GBX 2,360. The business has a 50 day moving average of GBX 1,730.88 and a 200-day moving average of GBX 1,893.97. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Laura Balan Balan purchased 3,500 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was purchased at an average price of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah acquired 315,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150. Insiders have purchased a total of 332,500 shares of company stock valued at $533,130,500 in the last quarter. 17.77% of the stock is currently owned by company insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.